Rafael (NYSE:RFL) Shares Up 4.2% – What’s Next?

Rafael Holdings, Inc. (NYSE:RFL)’s stock price was up 4.2% during trading on Thursday . The stock traded as high as $2.59 and last traded at $2.3870. Approximately 182,359 shares were traded during trading, an increase of 53% from the average daily volume of 119,023 shares. The stock had previously closed at $2.29.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on RFL shares. Weiss Ratings restated a “sell (d-)” rating on shares of Rafael in a research report on Tuesday, August 25th. Wall Street Zen upgraded shares of Rafael to a “hold” rating in a research report on Saturday, July 25th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Rafael Stock Down 2.3%

The firm has a market cap of $119.86 million, a price-to-earnings ratio of -3.39 and a beta of 0.40. The stock’s 50 day moving average is $2.22 and its 200 day moving average is $1.82.

Institutional Trading of Rafael

A number of institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new position in Rafael during the second quarter worth $50,000. Citadel Advisors LLC lifted its holdings in Rafael by 132.3% in the 3rd quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock worth $99,000 after purchasing an additional 41,335 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Rafael by 59.1% in the 1st quarter. Renaissance Technologies LLC now owns 89,138 shares of the company’s stock worth $111,000 after purchasing an additional 33,111 shares during the last quarter. Cable Car Capital LP bought a new stake in Rafael during the second quarter worth approximately $173,000. Finally, Kahn Brothers Group Inc. bought a new stake in Rafael during the second quarter worth approximately $494,000. 11.30% of the stock is currently owned by institutional investors and hedge funds.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.